[go: up one dir, main page]

WO1996033204A1 - Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf) - Google Patents

Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf) Download PDF

Info

Publication number
WO1996033204A1
WO1996033204A1 PCT/US1995/005155 US9505155W WO9633204A1 WO 1996033204 A1 WO1996033204 A1 WO 1996033204A1 US 9505155 W US9505155 W US 9505155W WO 9633204 A1 WO9633204 A1 WO 9633204A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
tnf
human
chimeric
cells
Prior art date
Application number
PCT/US1995/005155
Other languages
English (en)
Inventor
Marc Feldmann
Ravinder Nath Maini
James N. Woody
Original Assignee
The Kennedy Institute Of Rheumatology
Centocor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Kennedy Institute Of Rheumatology, Centocor, Inc. filed Critical The Kennedy Institute Of Rheumatology
Priority to JP8531685A priority Critical patent/JPH11503752A/ja
Priority to PCT/US1995/005155 priority patent/WO1996033204A1/fr
Priority to AU23657/95A priority patent/AU2365795A/en
Priority to EP95917696A priority patent/EP0871641A4/fr
Priority to CA002218522A priority patent/CA2218522A1/fr
Publication of WO1996033204A1 publication Critical patent/WO1996033204A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • TNF ⁇ tumor necrosis factor- ⁇
  • TNF ⁇ human non-monocytic tumor cell lines produce TNF (Rubin, et al., J. Exp . Med. 164:1350 (1986); Spriggs, et al . , Proc . Natl . Acad. Sci . USA 84:6563 (1987)) .
  • CD4+ and CD8+ peripheral blood T lymphocytes and some cultured T and B cell lines (Cuturi, et al . , J. Exp. Med.
  • TNF causes pro-inflammatory actions which result in tissue injury, such as inducing procoagulant activity on vascular endothelial cells (Pober, et al . , J. Immunol . 136 : 1680 (1986)), increasing the adherence of neutrophils and lymphocytes (Pober, et al . , J. Immunol . 138:3319 (1987) ) , and stimulating the release of platelet activating factor from macrophages, neutrophils and vascular endothelial cells (Camussi, et al., J " . Exp . Med. 166:1390 (1987)) .
  • TNF ⁇ has been implicated in inflammatory diseases, autoimmune diseases, viral, bacterial and parasitic infections, malignancies, and/or neurogenerative diseases and is a useful target for specific biological therapy in diseases, such as rheumatoid arthritis and Crohn's disease.
  • beneficialal effects in an open-label trial with a chimeric antibody to TNF ⁇ (cA2) have been reported with suppression of inflammation.
  • cA2 chimeric antibody to TNF ⁇
  • HAMA response human anti-mouse antibody response
  • subsequent administrations of chimeric antibodies have resulted in decreased therapeutic benefit in the patient.
  • anti-TNF murine mAb therapy in fourteen patients with severe septic shock were administered a murine anti-TNF mAb in a single dose from 0.4-10 mg/kg (Exley, A.R. et al . , Lancet 335:1275-1277 (1990)) .
  • the invention is based on the unexpected and surprising discovery that certain anti-TNF antibodies can be administered to patients suffering from relapse of a TNF- mediated disease with a magnitude of response that was the same or similar to that achieved with the initial treatment of the antibody.
  • the invention therefore, relates to a method of treating an individual having a TNF-mediated disease comprising administering to the individual multiple doses of an anti-TNF antibody wherein the second or subsequent dose is administered during or immediately prior to reoccurrence of the disease.
  • the invention also relates to the use of anti-TNF antibodies for the treatment of reoccurrence of a TNF-mediated disease previously treated with an anti-TNF antibody.
  • TNF-mediated diseases include chronic and debilitating disease states such as rheumatoid arthritis and Crohn's disease.
  • the invention permits the extended beneficial treatment of patients suffering from these chronic disease states.
  • Figure 1 is a line graph of the response magnitude of patients administered with a first cycle of 20 mg/kg and three cycles of 10 mg/kg of anti-TNF ⁇ antibody (cA2) .
  • the figure shows that the second and subsequent administrations resulted in a response that equalled or surpassed that of the first treatment cycle.
  • the solid line indicates the swollen joint count and the dotted line indicates the serum C-reactive protein (CRP) response.
  • Figure 2 is a bar graph of the duration of response of seven patients administered with at least two full cycles of anti-TNF ⁇ antibody (cA2) .
  • the invention relates to the discovery that anti-TNF antibodies can be administered to patients suffering from a TNF-mediated disease in multiple doses, even during relapse, with good to excellent alleviation of the symptoms of the disease in the second or subsequent administration.
  • the present invention also provides for anti-TNF antibodies in the form of pharmaceutical compositions, useful for therapeutic methods of the present invention for treating TNF-related pathologies.
  • Such antibodies, fragments, or regions will preferably have an affinity for hTNF ⁇ , expressed as Ka, of at least 10 8 M _1 , more preferably, at least 10 9 M "1 .
  • Preferred for human therapeutic use are high affinity antibodies, and fragments, regions and derivatives having potent in vivo TNF ⁇ -inhibiting and/or neutralizing activity, according to the present invention, that block TNF-induced IL-6 secretion.
  • Also preferred for human therapeutic uses are such high affinity anti-TNF ⁇ antibodies, and fragments, regions and derivatives thereof, that block TNF-induced procoagulant activity, including blocking of TNF-induced expression of cell adhesion molecules such as ELAM-I and ICAM-I and blocking of TNF mitogenic activity, in vivo and in vi tro.
  • Anti-TNF antibodies which can be used in the invention include monoclonal, chimeric, humanized, resurfaced or recombinant antibodies or fragments thereof which are characterized by high affinity to TNF and low toxicity (including HAMA and/or HACA response) .
  • an antibody wherein the individual components, such as the variable region, constant region and framework, individually and/or collectively possess low immunogenicity.
  • the antibodies of the present invention are characterized by their ability to treat patients for extended periods with good to excellent alleviation of symptoms and low toxicity. Low immunogenicity and/or high affinity, as well as other undefined properties, may contribute to the therapeutic results achieved.
  • Preferred antibodies are chimeric antibodies.
  • Chimeric antibodies are immunoglobulin molecules characterized by two or more segments or portions derived from different animal species.
  • the variable region of the chimeric antibody is derived from a non-human mammalian antibody, such as a murine mAb, and the immunoglobulin constant region is derived from a human immunoglobulin molecule.
  • a variable region with low immunogenicity is selected and combined with a human constant region which also has low immunogenicity, the combination also preferably having low immunogenicity.
  • “Low” immunogenicity is defined herein as raising significant HACA or HAMA responses in less than about 75%, or preferably less than about 50% of the patients treated and/or raising low titres in the patient treated (less than about 300, preferably less than about 100 measured with a double antigen enzyme immunoassay) .
  • the term "chimeric antibody” includes monovalent, divalent or polyvalent immunoglobulins.
  • a monovalent chimeric antibody is a dimer (HL) ) formed by a chimeric H chain associated through disulfide bridges with a chimeric L chain.
  • a divalent chimeric antibody is a tetramer (H2L2) formed by two HL dimers associated through at least one disulfide bridge.
  • a polyvalent chimeric antibody can also be produced, for example, by employing a CH region that aggregates (e.g., from an IgM H chain, or ⁇ chain) .
  • Antibodies comprise individual heavy (H) and/or light (L) immunoglobulin chains.
  • a chimeric H chain comprises an antigen binding region derived from the H chain of a non-human antibody specific for TNF, which is linked to at least a portion of a human H chain C region (CH) , such as CHI or CH2.
  • a chimeric L chain according to the present invention comprises an antigen binding region derived from the L chain of a non-human antibody specific for TNF, linked to at least a portion of a human L chain C region (CL) .
  • Chimeric antibodies and methods for their production have been described in the art (Morrison et al . , Proc. Na tl . Acad. Sci . USA 81:6851-6855 (1984); Boulianne et al . , Na ture 312:643-646 (1984) ; Neuberger et al . , Nature 314:268-270 (1985) ; Taniguchi et al . , European Patent Application 171496 (published February 19, 1985); Morrison et al .
  • the anti-TNF chimeric antibody can comprise, for example, two light chains and two heavy chains, each of the chains comprising at least part of a human constant region and at least part of a variable (V) region of non-human origin having specificity to human TNF, said antibody binding with high affinity to an inhibiting and/or neutralizing epitope of human TNF, such as the antibody cA2.
  • the antibody also includes a fragment or a derivative of such an antibody, such as one or more portions of the antibody chain, such as the heavy chain constant or variable regions, or the light chain constant or variable regions. Humanizing and resurfacing the antibody can further reduce the immunogenicity of the antibody. See, for example, Winter (U.S. Patent No.
  • Preferred antibodies of the present invention are high affinity human-murine chimeric anti-TNF antibodies, and fragments or regions thereof, that have potent inhibiting and/or neutralizing activity in vivo against human TNF ⁇ .
  • Such antibodies and chimeric antibodies can include those generated by immunization using purified recombinant TNF ⁇ or peptide fragments thereof comprising one or more epitopes .
  • a chimeric antibody is cA2 and antibodies which will competitively inhibit in vivo the binding to human TNF ⁇ of anti-TNF ⁇ murine mAb A2, chimeric mAb cA2, or an antibody having substantially the same specific binding characteristics, as well as fragments and regions thereof.
  • Preferred methods for determining mAb specificity and affinity by competitive inhibition can be found in Harlow, et al . , Antibodies : A Laboratory Manual , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988) , Colligan et al . , eds . , Current Protocols in Immunology, Greene Publishing Assoc.
  • the term "antigen binding region” refers to that portion of an antibody molecule which contains the amino acid residues that interact with an antigen and confer on the antibody its specificity and affinity for the antigen.
  • the antibody region includes the "framework" amino acid residues necessary to maintain the proper conformation of the antigen-binding residues.
  • the antigen binding region will be of murine origin. In other embodiments, the antigen binding region can be derived from other animal species, such as sheep, rabbit, rat or hamster.
  • Preferred sources for the DNA encoding such a non-human antibody include cell lines which produce antibody, preferably hybrid cell lines commonly known as hybridomas. A preferred hybridoma is the A2 hybridoma cell line.
  • an "antigen” is a molecule or a portion of a molecule capable of being bound by an antibody which is additionally capable of inducing an animal to produce antibody capable of selectively binding to an epitope of that antigen.
  • An antigen can have one or more than one epitope.
  • epitope is meant to refer to that portion of the antigen capable of being recognized by and bound by an antibody at one or more of the Ab's antigen binding region.
  • Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and have specific three dimensional structural characteristics as well as specific charge characteristics.
  • inhibiting and/or neutralizing epitope is intended an epitope, which, when bound by an antibody, results in loss of biological activity of the molecule containing the epitope, in vivo or in vi tro, more preferably in vivo, including binding of TNF to a TNF receptor.
  • Epitopes of TNF have been identified within amino acids 1 to about 20, about 56 to about 77, about 108 to about 127 and about 138 to about 149.
  • the antibody binds to an epitope comprising at least about 5 amino acids of TNF within TNF residues from about 87 to about 107, about 59 to about 80 or a combination thereof.
  • epitopes include at least about 5 amino acids and less than about 22 amino acids embracing or overlapping one or more of these regions .
  • epitopes of TNF which are recognized by, and/or binds with anti-TNF activity, an antibody, and fragments, and variable regions thereof, include:
  • Murine antibodies which can be used in the preparation of the antibodies of the present invention have also been described in Rubin et al . , EP0218868, April 22, 1987; Yone et al . , EP0288088, October 26, 1988; Liang, et al . , Biochem. Biophys . Res . Comm. 137:847-854 (1986) ; Meager, et al . , Hybridoma 3:1 (1987); Fendly et al . , Hybridoma 6:359-369 (1987) ; Bringman, et al . , Hybridoma 6:489-507
  • the TNF ⁇ -specific murine mAb of the present invention can be produced in large quantities by injecting hybridoma or transfectoma cells secreting the antibody into the peritoneal cavity of mice and, after appropriate time, harvesting the ascites fluid which contains a high titer of the mAb, and isolating the mAb therefrom.
  • hybridoma e.g., rat or human
  • hybridoma cells are preferably grown in irradiated or athymic nude mice.
  • the antibodies can be produced by culturing hybridoma or transfectoma cells in vi tro and isolating secreted mAb from the cell culture medium or recombinantly, in eukaryotic or prokaryotic cells.
  • the antibody is a mAb which binds amino acids of an epitope of TNF recognized by A2, rA2 or cA2, which is produced by a hybridoma or by a recombinant host.
  • the antibody is a chimeric antibody which recognizes an epitope recognized by A2.
  • the antibody is a chimeric antibody designated as chimeric A2 (cA2) .
  • murine mAb A2 of the present invention is produced by a cell line designated cl34A.
  • Chimeric antibody cA2 is produced by a cell line designated cl68A.
  • cl68A was deposited at the American Type Culture Collection, Rockville, Maryland, as a "Culture Safe Deposit.”
  • the invention also provides for "derivatives" of the antibodies including fragments, regions or proteins encoded by truncated or modified genes to yield molecular species functionally resembling the immunoglobulin fragments.
  • the modifications include, but are not limited to, addition of genetic sequences coding for cytotoxic proteins such as plant and bacterial toxins.
  • the fragments and derivatives can be produced from appropriate cells, as is known in the art.
  • anti-TNF antibodies, fragments and regions can be bound to cytotoxic proteins or compounds in vi tro, to provide cytotoxic anti-TNF antibodies which would selectively kill cells having TNF on their surface.
  • Fragments include, for example, Fab, Fab' , F(ab')2 and Fv.
  • fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and can have less non-specific tissue binding than an intact antibody (Wahl et al . , J. Nucl . Med. 24:316-325 (1983)) .
  • fragments are produced from intact antibodies using methods well known in the art, for example by proteolytic cleavage with enzymes such as papain (to produce Fab fragments) or pepsin " (to produce F(ab')2 fragments) .
  • Recombinant and/or chimeric murine-human or human-human antibodies that inhibit TNF can be provided according to the present invention using known techniques based on the teaching provided herein. See, e.g., Ausubel et al . , eds. Current Protocols in Molecular Biology, Wiley Interscience, N.Y. (1987, 1992, 1993) ; and Sambrook et al . Molecular
  • the DNA encoding an anti-TNF antibody of the present invention can be genomic DNA or cDNA which encodes at least one of the heavy chain constant region (He) , the heavy chain variable region (He) , the light chain variable region (Lv) and the light chain constant regions (Lc) .
  • a convenient alternative to the use of chromosomal gene fragments as the source of DNA encoding the murine V region antigen-binding segment is the use of cDNA for the construction of chimeric immunoglobulin genes, e.g., as reported by Liu et al . ( Proc . Natl . Acad. Sci . , USA 84:3439 (1987) and J.
  • cDNA requires that gene expression elements appropriate for the host cell be combined with the gene in order to achieve synthesis of the desired protein.
  • the use of cDNA sequences is advantageous over genomic sequences (which contain introns) , in that cDNA sequences can be expressed in bacteria or other hosts which lack appropriate RNA splicing systems. An example of such a preparation is set forth below.
  • the genetic code is degenerate, more than one codon can be used to encode a particular amino acid.
  • one or more different oligonucleotides can be identified, each of which would be capable of encoding the amino acid.
  • the probability that a particular oligonucleotide will, in fact, constitute the actual XXX- encoding sequence can be estimated by considering abnormal base pairing relationships and the frequency with which a particular codon is actually used (to encode a particular amino acid) in eukaryotic or prokaryotic cells expressing an anti-TNF antibody or fragment.
  • Such "codon usage rules" are disclosed by Lathe, et al . , J. Molec. Biol . 183 : 1- 12 (1985) .
  • amino acid sequence can be encoded by only a single oligonucleotide
  • amino acid sequence can be encoded by any of a set of similar oligonucleotides.
  • all of the members of this set contain oligonucleotides which are capable of encoding the peptide fragment and, thus, potentially contain the same oligonucleotide sequence as the gene which encodes the peptide fragment
  • only one member of the set contains the nucleotide sequence that is identical to the nucleotide sequence of the gene.
  • this member is present within the set, and is capable of hybridizing to DNA even in the presence of the other members of the set, it is possible to employ the unfractionated set of oligonucleotides in the same manner in which one would employ a single oligonucleotide to clone the gene that encodes the protein.
  • the oligonucleotide, or set of oligonucleotides, containing the theoretical "most probable" sequence capable of encoding an anti-TNF antibody or fragment including a variable or constant region is used to identify the sequence of a complementary oligonucleotide or set of oligonucleotides which is capable of hybridizing to the "most probable" sequence, or set of sequences.
  • An oligonucleotide containing such a complementary sequence can be employed as a probe to identify and isolate the variable or constant region anti-TNF gene (Sambrook et al. , infra) .
  • a suitable oligonucleotide, or set of oligonucleotides, which is capable of encoding a fragment of the variable or constant anti-TNF region (or which is complementary to such an oligonucleotide, or set of oligonucleotides) is identified (using the above-described procedure) , synthesized, and hybridized by means well known in the art, against a DNA or, more preferably, a cDNA preparation derived from cells which are capable of expressing anti-TNF antibodies or variable or constant regions thereof.
  • Single stranded oligonucleotide molecules complementary to the "most probable" variable or constant anti-TNF region peptide coding sequences can be synthesized using procedures which are well known to those of ordinary skill in the art (Belagaje, et al . , J. Biol . Chem. 254:5765-5780 (1979); Maniatis, et al . , In : Molecular Mechanisms in the Control of Gene Expression, Nierlich, et al . , Eds., Acad. Press, NY (1976) ; Wu, et al. , Prog. Nucl . Acid Res . Molec . Biol .
  • DNA synthesis can be achieved through the use of automated synthesizers. Techniques of nucleic acid hybridization are disclosed by Sambrook et al . (infra) , and by Haynes, et al. (In: Nucleic Acid Hybridization, A Practical Approach, IRL Press, Washington, DC (1985)), which references are herein incorporated by reference. Techniques such as, or similar to, those described above have successfully enabled the cloning of genes for human aldehyde dehydrogenases (Hsu, et al . , Proc . Natl . Acad . Sci .
  • a library of expression vectors is prepared by cloning DNA or, more preferably, cDNA (from a cell capable of expressing an anti- TNF antibody or variable or constant region) into an expression vector.
  • the library is then screened for members capable of expressing a protein which competitively inhibits the binding of an anti-TNF antibody, such as A2 or cA2, and which has a nucleotide sequence that is capable of encoding polypeptides that have the same amino acid sequence as anti-TNF antibodies or fragments thereof.
  • DNA, or more preferably cDNA is extracted and purified from a cell which is capable of expressing an anti-TNF antibody or fragment.
  • the purified cDNA is fragmentized (by shearing, endonuclease digestion, etc.) to produce a pool of DNA or cDNA fragments.
  • DNA or cDNA fragments from this pool are then cloned into an expression vector in order to produce a genomic library of expression vectors whose members each contain a unique cloned DNA or cDNA fragment such as in a lambda phage library, expression in prokaryotic cell (e.g., bacteria) or eukaryotic cells, (e.g., mammalian, yeast, insect or, fungus) .
  • prokaryotic cell e.g., bacteria
  • eukaryotic cells e.g., mammalian, yeast, insect or, fungus
  • nucleic acid encoding such variable or constant anti-TNF regions is isolated, the nucleic acid can be appropriately expressed in a host cell, along with other constant or variable heavy or light chain encoding nucleic acid, in order to provide recombinant mabs that bind TNF with inhibitory activity.
  • Such antibodies preferably include a murine or human anti-TNF variable region which contains a framework residue having complementarity determining residues which are responsible for antigen binding.
  • Human genes which encode the constant (C) regions of the chimeric antibodies, fragments and regions of the present invention can be derived from a human fetal liver library, by known methods. Human C region genes can be derived from any human cell including those which express and produce human immunoglobulins.
  • the human CH region can be derived from any of the known classes or isotypes of human H chains, including gamma, ⁇ , ⁇ , ⁇ or e, and subtypes thereof, such as Gl, G2, G3 and G4.
  • the CH region is derived from gamma 1 (IgGl) , gamma 3 (IgG3), gamma 4 (IgG4), or ⁇ (IgM) .
  • the human CL region can be derived from either human L chain isotype, kappa or lambda.
  • Human immunoglobulin C regions are obtained from human cells by standard cloning techniques (Sambrook, et al. (Molecular Cloning: A Laboratory Manual , 2nd Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989) and Ausubel et al . , eds. Current Protocols in Molecular Biology (1987-1993)) .
  • Human C region genes are readily available from known clones containing genes representing the two classes of L chains, the five classes of H chains and subclasses thereof.
  • Chimeric antibody fragments, such as F(ab')2 and Fab can be prepared by designing a chimeric H chain gene which is appropriately truncated.
  • a chimeric gene encoding an H chain portion of an F(ab' )2 fragment would include DNA sequences encoding the CHI domain and hinge region of the H chain, followed by a translational stop codon to yield the truncated molecule.
  • the murine, human and chimeric antibodies, fragments and regions are produced by cloning DNA segments encoding the H and L chain antigen-binding regions of a TNF-specific antibody, and joining these DNA segments to DNA segments encoding CH and CL regions, respectively, to produce murine, human or chimeric immunoglobulin-encoding genes.
  • a fused chimeric gene is created which comprises a first DNA segment that encodes at least the antigen-binding region of non-human origin, such as a functionally rearranged V region with joining (J) segment, linked to a second DNA segment encoding at least a part of a human C region.
  • cDNA encoding the antibody V and C regions and the method of producing a chimeric antibody can involve several steps, outlined below: 1. isolation of messenger RNA (mRNA) from the cell line producing an anti-TNF antibody and from optional additional antibodies supplying heavy and light constant regions; cloning and cDNA production therefrom;
  • mRNA messenger RNA
  • L and H chains in selected hosts, including prokaryotic and eukaryotic cells to provide murine-murine, human-murine, human-human or human-murine antibodies.
  • H and L chain J regions have different sequences, but a high degree of sequence homology exists (greater than 80%) among each group, especially near the C region. This homology is exploited in this method and consensus sequences of H and L chain J regions can be used to design oligonucleotides for use as primers for introducing useful restriction sites into the J region for subsequent linkage of V region segments to human C region segments.
  • C region cDNA vectors prepared from human cells can be modified by site-directed mutagenesis to place a restriction site at the analogous position in the human sequence.
  • Ck human kappa chain C
  • Cgamma-1 human gamma-1 C region
  • the alternative method based upon genomic C region clones as the source for C region vectors would not allow these genes to be expressed in bacterial systems where enzymes needed to remove intervening sequences are absent .
  • Cloned V region segments are excised and ligated to L or H chain C region vectors.
  • the human Cgamma-1 region can be modified by introducing a termination codon thereby generating a gene sequence which encodes the H chain portion of an Fab molecule.
  • the coding sequences with linked V and C regions are then transferred into appropriate expression vehicles for expression in appropriate hosts, prokaryotic or eukaryotic.
  • Two coding DNA sequences are said to be "operably linked” if the linkage results in a continuously translatable sequence without alteration or interruption of the triplet reading frame.
  • a DNA coding sequence is operably linked to a gene expression element if the linkage results in the proper function of that gene expression element to result in expression of the coding sequence.
  • Expression vehicles include plasmids or other vectors. Preferred among these are vehicles carrying a functionally complete human CH or CL chain sequence having appropriate restriction sites engineered so that any VH or VL chain sequence with appropriate cohesive ends can be easily inserted therein. Human CH or CL chain sequence-containing vehicles thus serve as intermediates for the expression of any desired complete H or L chain in any appropriate host.
  • a chimeric antibody such as a mouse-human or human-human, will typically be synthesized from genes driven by the chromosomal gene promoters native to the mouse H and L chain V regions used in the constructs; splicing usually occurs between the splice donor site in the mouse J region and the splice acceptor site preceding the human C region and also at the splice regions that occur within the human C, region; polyadenylation and transcription termination occur at native chromosomal sites downstream of the human coding regions.
  • a nucleic acid sequence encoding at least one anti-TNF antibody fragment may be recombined with vector DNA in accordance with conventional techniques, including blunt-ended or staggered-ended termini for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases. Techniques for such manipulations are disclosed, e.g., by Ausubel, infra, Sambrook, infra, entirely incorporated herein by reference, and are well known in the art.
  • a nucleic acid molecule such as DNA is "capable of expressing" a polypeptide if it contains nucleotide sequences which contain transcriptional and translational regulatory information and such sequences are “operably linked” to nucleotide sequences which encode the polypeptide.
  • An operable linkage is a linkage in which the regulatory DNA sequences and the DNA sequence sought to be expressed are connected in such a way as to permit gene expression as anti-TNF .peptides or Ab fragments in recoverable amounts.
  • the precise nature of the regulatory regions needed for gene expression may vary from organism to organism, as is well known in the analogous art. See, e.g., Sambrook, supra and Ausubel supra .
  • Preferred hosts are bacterial or eukaryotic hosts including bacteria, yeast, insects, fungi, bird and mammalian cells either in vivo, or in si tu, or host cells of mammalian, insect, bird or yeast origin. It is preferred that the mammalian cell or tissue is of human, primate, hamster, rabbit, murine, rat, other rodent, cow, pig, sheep, horse, goat, dog or cat origin.
  • yeast ubiquitin hydrolase system in vivo synthesis of ubiquitin-transmembrane polypeptide fusion proteins may be accomplished.
  • the fusion proteins so produced may be processed in vivo or purified and processed in vi tro, allowing synthesis of an anti-TNF antibody or fragment of the present invention with a specified amino terminus sequence.
  • problems associated with retention of initiation codon-derived methionine residues in direct yeast (or bacterial) expression may be avoided.
  • Any of a series of yeast gene expression systems incorporating promoter and termination elements from the actively expressed genes coding for glycolytic enzymes produced in large quantities when yeast are grown in mediums rich in glucose can be utilized to obtain anti-TNF antibody fragments of the present invention.
  • Known glycolytic genes can also provide very efficient transcriptional control signals.
  • the promoter and terminator signals of the phosphoglycerate kinase gene can be utilized.
  • Production of anti-TNF antibody fragments or functional derivatives thereof in insects can be achieved, for example, by infecting the insect host with a baculovirus engineered to express transmembrane polypeptide by methods known to those of skill. See Ausubel et al. , eds. Current Protocols in Molecular Biology Wiley Interscience, ⁇ 16.8-16.11 (1987, 1993) .
  • the introduced nucleotide sequence will be incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host.
  • a plasmid or viral vector capable of autonomous replication in the recipient host.
  • Any of a wide variety of vectors may be employed for this purpose. See, e.g., Ausubel et al . , infra, ⁇ 1.5, 1.10, 7.1, 7.3, 8.1, 9.6, 9.7, 13.4, 16.2, 16.6, and 16.8-16.11.
  • Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector may be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species.
  • Preferred prokaryotic vectors known in the art include plasmids such as those capable of replication in E. coli (such as, for example, pBR322, ColEl, pSClOl, pACYC 184, ⁇ VX) .
  • Such plasmids are, for example, disclosed by Maniatis, T. , et al . (Molecular Cloning, A Laboratory Manual , Second Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989) ; Ausubel, infra .
  • Bacillus plasmids include pC194, pC221, pT127, etc. Such plasmids are disclosed by Gryczan, T.
  • Suitable Streptomyces plasmids include pIJlOl (Kendall, K.J., et al . , J. Bacteriol . 169:4177-4183 (1987)) , and Streptomyces bacteriophages such as ⁇ C31 (Chater, K.F., et al . , In: Sixth International Symposium on Ac tinomyce tales Biology, Akademiai Kaido, Budapest, Hungary (1986) , pp. 45-54) .
  • gene expression elements useful for the expression of cDNA encoding anti-TNF antibodies or peptides include, but are not limited to (a) viral transcription promoters and their enhancer elements, such as the SV40 early promoter (Okayama, et al . , Mol . Cell . Biol .
  • Rous sarcoma virus LTR Rous sarcoma virus LTR (Gorman, et al . , Proc . Na tl . Acad. Sci . , USA 79 : 6111 (1982)) , and Moloney murine leukemia virus LTR (Grosschedl, et al . , Cell 41:885 (1985)); (b) splice regions and polyadenylation sites such as those derived from the SV40 late region (Okayarea et al . , infra) ; and (c) polyadenylation sites such as in SV40 (Okayama et al . , infra) .
  • Immunoglobulin cDNA genes can be expressed as described by Liu et al. , infra, and Weidle et al . , Gene 51:21 (1987), using as expression elements the SV40 early promoter and its enhancer, the mouse immunoglobulin H chain promoter enhancers, SV40 late region mRNA splicing, rabbit S-globin intervening sequence, immunoglobulin and rabbit S-globin polyadenylation sites, and SV40 polyadenylation elements.
  • immunoglobulin genes comprised of part cDNA, part genomic DNA (Whittle et al .
  • the transcriptional promoter can be human cytomegalovirus
  • the promoter enhancers can be cytomegalovirus and mouse/human immunoglobulin
  • mRNA splicing and polyadenylation regions can be the native chromosomal immunoglobulin sequences.
  • the transcriptional promoter is a viral LTR sequence
  • the transcriptional promoter enhancers are either or both the mouse immunoglobulin heavy chain enhancer and the viral LTR enhancer
  • the splice region contains an intron of greater than 31 bp
  • the polyadenylation and transcription termination regions are derived from the native chromosomal sequence corresponding to the immunoglobulin chain being synthesized.
  • cDNA sequences encoding other proteins are combined with the above-recited expression elements to achieve expression of the proteins in mammalian cells.
  • Each fused gene is assembled in, or inserted into, an expression vector.
  • Recipient cells capable of expressing the chimeric immunoglobulin chain gene product are then transfected singly with an anti-TNF antibody or chimeric H or chimeric L chain-encoding gene, or are co-transfected with a chimeric H and a chimeric L chain gene.
  • the transfected recipient cells are cultured under conditions that permit expression of the incorporated genes and the expressed immunoglobulin chains or intact antibodies or fragments are recovered from the culture.
  • the fused genes encoding the anti-TNF antibody or chimeric H and L chains, or portions thereof are assembled in separate expression vectors that are then used to co-transfect a recipient cell.
  • Each vector can contain two selectable genes, a first selectable gene designed for selection in a bacterial system and a second selectable gene designed for selection in a eukaryotic system, wherein each vector has a different pair of genes.
  • This strategy results in vectors which first direct the production, and permit amplification, of the fused genes in a bacterial system.
  • the genes so produced and amplified in a bacterial host are subsequently used to co-transfect a eukaryotic cell, and allow selection of a co-transfected cell carrying the desired transfected genes.
  • selectable genes for use in a bacterial system are the gene that confers resistance to ampicillin and the gene that confers resistance to chloramphenicol .
  • Preferred selectable genes for use in eukaryotic transfectants include the xanthine guanine phosphoribosyl transferase gene (designated gpt) and the phosphotransferase gene from Tn5 (designated neo) .
  • Selection of cells expressing gpt is based on the fact that the enzyme encoded by this gene utilizes xanthine as a substrate for purine nucleotide synthesis, whereas the analogous endogenous enzyme cannot .
  • mycophenolic acid which blocks the conversion of inosine monophosphate to xanthine monophosphate
  • xanthine only cells expressing the gpt gene can survive.
  • the product of the neo blocks the inhibition of protein synthesis by the antibiotic G418 and other antibiotics of the neomycin class.
  • the two selection procedures can be used simultaneously or sequentially to select for the expression of immunoglobulin chain genes introduced on two different DNA vectors into a eukaryotic cell. It is not necessary to include different selectable markers for eukaryotic cells; an H and an L chain vector, each containing the same selectable marker can be co-transfected. After selection of the appropriately resistant cells, the majority of the clones will contain integrated copies of both H and L chain vectors and/or anti-TNF antibody. Alternatively, the fused genes encoding the chimeric H and L chains can be assembled on the same expression vector.
  • the preferred recipient cell line is a myeloma cell.
  • Myeloma cells can synthesize, assemble and secrete immunoglobulins encoded by transfected immunoglobulin genes and possess the mechanism.for glycosylation of the immunoglobulin.
  • a particularly preferred recipient cell is the myeloma cell SP2/0 (ATCC #CRL 8287) . SP2/0 cells produce only immunoglobulin encoded by the transfected genes.
  • Myeloma cells can be grown in culture or in the peritoneal cavity of a mouse, where secreted immunoglobulin can be obtained from ascites fluid.
  • Other suitable recipient cells include lymphoid cells such as B lymphocytes of human or non-human origin, hybridoma cells of human or non-human origin, or interspecies heterohybridoma cells.
  • the expression vector carrying a chimeric antibody construct of the present invention can be introduced into an appropriate host cell by any of a variety of suitable means, including such biochemical means as transformation, transfection, conjugation, protoplast fusion, calcium phosphate-precipitation, and application with polycations such as diethylaminoethyl (DEAE) dextran, and such mechanical means as electroporation, direct microinjection, and microprojectile bombardment (Johnston et al . , Science 240:1538 (1988)) .
  • a preferred way of introducing DNA into lymphoid cells is by electroporation (Potter et al . , Proc. Natl . Acad. Sci .
  • lysozyme is used to strip cell walls from catarrhal harboring the recombinant plasmid containing the chimeric antibody gene.
  • the resulting spheroplasts are fused with myeloma cells with polyethylene glycol.
  • the immunoglobulin genes can also be expressed in nonlymphoid mammalian cells or in other eukaryotic cells, such as yeast, or in prokaryotic cells, in particular bacteria.
  • Yeast provides substantial advantages over bacteria for the production of immunoglobulin H and L chains. Yeasts carry out post-translational peptide modifications including glycosylation.
  • Yeast recognizes leader sequences of cloned mammalian gene products and secretes peptides bearing leader sequences (i.e., pre-peptides) (Hitzman, et al . , 11 th International Conference on Yeast, Genetics and Molecular Biology, Montpelier, France, September 13-17, 1982) .
  • Yeast gene expression systems can be routinely evaluated for the levels of production, secretion and the stability of anti-TNF peptides, antibody and assembled murine and chimeric antibodies, fragments and regions thereof.
  • Yeast gene expression systems incorporating promoter and termination elements from the actively expressed genes coding for glycolytic enzymes produced in large quantities when yeasts are grown in media rich in glucose, for example, can be utilized.
  • Known glycolytic genes can also provide very efficient transcription control signals.
  • the promoter and terminator signals of the phosphoglycerate kinase (PGK) gene can be utilized.
  • PGK phosphoglycerate kinase
  • a number of approaches can be taken for evaluating optimal expression plasmids for the expression of cloned immunoglobulin cDNAs in yeast (see Glover, ed. , DNA Cloning, Vol . II, pp45-66, IRL Press, 1985) .
  • Bacterial strains can also be utilized as hosts for the production of antibody molecules or peptides described by this invention, E. coli K12 strains such as E. coli W3110 (ATCC 27325) , and other enterobacteria such as Salmonella typhimurium or Serratia marcescen ⁇ , and various Pseudomonas species can be used.
  • Plasmid vectors containing replicon and control sequences which are derived from species compatible with a host cell are used in connection with these bacterial hosts.
  • the vector carries a replication site, as well as specific genes which are capable of providing phenotypic selection in transformed cells.
  • Preferred hosts are mammalian cells, grown in vi tro or in vivo .
  • Mammalian cells provide post-translational modifications to immunoglobulin protein molecules including leader peptide removal, folding and assembly of H and L chains, glycosylation of the antibody molecules, and secretion of functional antibody protein.
  • Mammalian cells which can be useful as hosts for the production of antibody proteins include cells of fibroblast origin, such as Vero (ATCC CRL 81) or CH0-K1 (ATCC CRL 61) .
  • fibroblast origin such as Vero (ATCC CRL 81) or CH0-K1 (ATCC CRL 61) .
  • Many vector systems are available for the expression of cloned anti TNF peptide H and L chain genes in mammalian cells (see Glover, ed., DNA Cloning, Vol . II, ppl43-238, IRL Press, 1985) . Different approaches can be followed to obtain complete H2L2 antibodies.
  • H and L chains in the same cells to achieve intracellular association and linkage of H and L chains into complete tetrameric H2L2 antibodies.
  • the co-expression can occur by using either the same or different plasmids in the same host. Genes for both H and L chains can be placed into the same plasmid, which is then transfected into cells, thereby selecting directly for cells that express both chains. Alternatively, cells can be transfected first with a plasmid encoding one chain, for example the L chain, followed by transfection of the resulting cell line with an H chain plasmid containing a second selectable marker.
  • H2L2 molecules via either route could be transfected with plasmids encoding additional copies of peptides, H, L, or H plus L chains in conjunction with additional selectable markers to generate cell lines with enhanced properties, such as higher production of assembled H2L2 antibody molecules or enhanced stability of the transfected cell lines .
  • a murine-human chimeric anti-human TNF ⁇ MAb was developed with high affinity, epitope specificity and the ability to neutralize the cytotoxic effects of human TNF.
  • Chimeric A2 anti-TNF consists of the antigen binding variable region of the high-affinity neutralizing mouse antihuman TNF IgGl antibody, designated A2, and the constant regions of a human IgGl, kappa immunoglobulin.
  • the human IgGl Fc region improves allogeneic antibody effector function, increases the circulating serum half-life and decreases the immunogenicity of the antibody.
  • the avidity and epitope specificity of the chimeric A2 is derived from the variable region of the murine A2.
  • cross-competition for TNF was observed between chimeric and murine A2, indicating an identical epitope specificity of cA2 and murine A2.
  • the specificity of cA2 for TNF- ⁇ was confirmed by its inability to neutralize the cytotoxic effects of lymphotoxin (TNF- ⁇ ) .
  • Chimeric A2 neutralizes the cytotoxic effect of both natural and recombinant human TNF in a dose dependent manner. From binding assays of cA2 and recombinant human TNF, the affinity constant of cA2 was calculated to be 1.8xl0 9 Ml.
  • the anti-TNF antibodies, fragments and/or derivatives are useful for treating a subject having a pathology or condition associated with abnormal levels of a substance reactive with an anti-TNF antibody, in particular TNF in excess of, or less than, levels present in a normal healthy subject, where such excess or diminished levels occur in a systemic, localized or particular tissue type or location in the body.
  • tissue types can include, but are not limited to, blood, lymph, CNS, liver, kidney, spleen, heart muscle or blood vessels, brain or spinal cord white matter or grey matter, cartilage, ligaments, tendons, lung, pancreas, ovary, testes, prostate.
  • TNF related pathologies or diseases include, but are not limited to, the following:
  • A acute and chronic immune and autoimmune pathologies, such as systemic lupus erythematosus (SLE) , rheumatoid arthritis, thyroiditis, graft versus host disease, scleroderma, diabetes mellitus, Graves' disease, and the like;
  • SLE systemic lupus erythematosus
  • rheumatoid arthritis thyroiditis
  • graft versus host disease graft versus host disease
  • scleroderma diabetes mellitus
  • Graves' disease and the like
  • infections including, but not limited to, sepsis syndrome, cachexia, circulatory collapse and shock resulting from acute or chronic bacterial infection, acute and chronic parasitic and/or infectious diseases, bacterial, viral or fungal, such as a HIV, AIDS (including symptoms of cachexia, autoimmune disorders, AIDS dementia complex and infections);
  • C inflammatory diseases, such as chronic inflammatory pathologies and vascular inflammatory pathologies, including chronic inflammatory pathologies such as sarcoidosis, chronic inflammatory bowel disease, ulcerative colitis, and Crohn's pathology and vascular inflammatory pathologies, such as, but not limited to, disseminated intravascular coagulation, atherosclerosis, and Kawasaki's pathology:
  • (D) neurodegenerative diseases including, but are not limited to, demyelinating diseases, such as multiple sclerosis and acute transverse myelitis; extrapyramidal and cerebellar disorders' such as lesions of the corticospinal system; disorders of the basal ganglia or cerebellar disorders; hyperkinetic movement disorders such as Huntington's Chorea and senile chorea; drug-induced movement disorders, such as those induced by drugs which block CNS dopamine receptors; hypokinetic movement disorders, such as Parkinson's disease; Progressive supranucleo palsy; Cerebellar and Spinocerebellar Disorders, such as astructural lesions of the cerebellum; spinocerebellar degenerations (spinal ataxia, Friedreich's ataxia, cerebellar cortical degenerations, multiple systems degenerations (Mencel, Dejerine-Thomas, Shi-Drager, and
  • MachadoJoseph MachadoJoseph
  • systemic disorders Refsum' s disease, abetalipoprotemia, ataxia, telangiectasia, and mitochondrial multi.system disorder
  • demyelinating core disorders such as multiple sclerosis, acute transverse myelitis
  • disorders of the motor unit such as neurogenic muscular atrophies (anterior horn cell degeneration, such as amyotrophic lateral sclerosis, infantile spinal muscular atrophy and juvenile spinal muscular atrophy); Alzheimer's disease; Down's Syndrome in middle age; Diffuse Lewy body disease; Senile Dementia of Lewy body type; Wernicke-Korsakoff syndrome; chronic alcoholism; Creutzfeldt-Jakob disease; Subacute sclerosing panencephalitis, Hallerrorden-Spatz disease; and Dementia pugilistica, or any subset thereof; (E) malignant pathologies involving TNF-secreting tumors or other
  • reoccurrence in the case of rheumatoid arthritis, a reoccurrence can include the experience of one or more of swollen joints, morning stiffness or joint tenderness.
  • Anti-TNF antibodies can be administered by any means that enables the active agent to reach the agent's site of action in the body of a mammal. The primary focus is the ability to reach and bind with TNF released by monocytes and macrophages or other TNF producing cells. Because proteins are subject to being digested when administered orally, parenteral administration, i. e., intravenous, subcutaneous, intramuscular, would ordinarily be used to optimize absorption.
  • Anti-TNF antibodies can be administered either as individual therapeutic agents or in combination with other therapeutic agents. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • the dosage administered will, of course, vary depending upon known factors such as the pharmacodynamic characteristics of the particular agent, and its mode and route of administration; age, health, and weight of the recipient; nature and extent of symptoms, kind of concurrent treatment, frequency of treatment, and the effect desired.
  • a daily dosage of active ingredient can be about 0.01 to 100 milligrams per kilogram of body weight. Ordinarily 1 to 40 milligrams per kilogram per day given in divided doses 1 to 6 times a day or in sustained release form is effective to obtain desired results.
  • the second or subsequent administration can be administered at a dosage which is the same, less than or greater than the initial or previous dose administered to the patient.
  • the second or subsequent administration is preferably during or immediately prior to relapse or a flare-up of the disease or symptoms of the disease.
  • the second and subsequent administrations can be given between about 5 to 30 weeks or about 10 to 25 weeks from the previous administration.
  • Two, three, four or more total administrations can be delivered to the patient, as needed.
  • Dosage forms (composition) suitable for internal administration generally contain from about 0.1 milligram to about 500 milligrams of active ingredient per unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.
  • anti-TNF antibodies or fragments can be formulated as a solution, suspension, emulsion or lyophilized powder in association with a pharmaceutically acceptable parenteral vehicle.
  • a pharmaceutically acceptable parenteral vehicle examples include water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Liposomes and nonaqueous vehicles such as fixed oils can also be used.
  • the vehicle or lyophilized powder can contain additives that maintain isotonicity (e.g., sodium chloride, mannitol) and chemical stability (e.g., buffers and preservatives) .
  • the formulation is sterilized by commonly used techniques.
  • Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field of art.
  • a parenteral composition suitable for administration by injection is prepared by dissolving 1.5% by weight of active ingredient in 0.9% sodium chloride solution.
  • Anti-TNF antibodies of this invention can be adapted for therapeutic efficacy by virtue of their ability to mediate antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC) against cells having TNF associated with their surface.
  • ADCC antibody-dependent cellular cytotoxicity
  • CDC complement-dependent cytotoxicity
  • an endogenous source or an exogenous source of effector cells (for ADCC) or complement components (for CDC) can be utilized.
  • the murine and chimeric antibodies, fragments and regions of this invention, their fragments, and derivatives can be used therapeutically as immunoconjugates (see for review: Dillman, R.O., Ann. J ⁇ t. Med.
  • Such peptides or Abs can be coupled to cytotoxic proteins, including, but not limited to ricin-A, Pseudomonas toxin and Diphtheria toxin.
  • cytotoxic proteins including, but not limited to ricin-A, Pseudomonas toxin and Diphtheria toxin.
  • Toxins conjugated to antibodies or other ligands or peptides are well known in the art (see, for example, Olsnes, S. et al . , Immunol . Today 10:291-295 (1989)) .
  • Plant and bacterial toxins typically kill cells by disrupting the protein synthetic machinery.
  • Anti-TNF antibodies can be conjugated to additional types of therapeutic moieties including, but not limited to, radionuclides, therapeutic agents, cytotoxic agents and drugs.
  • radionuclides which can be coupled to antibodies and delivered in vivo to sites of antigen include 212Bi,131I, 186Re, and 90Y, which list is not intended to be exhaustive.
  • the radionuclides exert their cytotoxic effect by locally irradiating the cells, leading to various intracellular lesions, as is known in the art of radiotherapy.
  • Cytotoxic drugs which can be conjugated to anti-TNF antibodies and subsequently used for in vivo therapy include, but are not limited to, daunorubicin, doxorubicin, methotrexate, and Mitomycin C. Cytotoxic drugs interfere with critical cellular processes including DNA, RNA, and protein synthesis. For a description of these classes of drugs which are well known in the art, and their mechanisms of action, see Goodman, et al . , Goodman and Gilman ' s THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 8th Ed., Macmillan Publishing Co., 1990.
  • Anti-TNF antibodies can be advantageously utilized in combination with other monoclonal or murine and chimeric antibodies, fragments and regions, or with lymphokines or hemopoietic growth factors, etc., which serve to increase the number or activity of effector cells which interact with the antibodies.
  • Anti-TNF antibodies, fragments or derivatives can also be used in combination with TNF therapy to block undesired side effects of TNF.
  • Recent approaches to cancer therapy have included direct administration of TNF to cancer patients or immunotherapy of cancer patients with lymphokine activated killer (LAK) cells (Rosenberg et al . , New Eng. J. Med. 313:1485-1492 (1985)) or tumor infiltrating lymphocytes (TIL) (Kurnick et al. (Clin .
  • TIL which have been transfected with the TNF gene to produce large amounts of TNF.
  • Such therapeutic approaches are likely to be associated with a number of undesired side effects caused by the pleiotropic actions of TNF as described herein and known in the related arts.
  • these side effects can be reduced by concurrent treatment of a subject receiving TNF or cells producing large amounts of TIL with the antibodies, fragments or derivatives of the present invention.
  • Effective doses are as described above. The dose level will require adjustment according to the dose of TNF or TNF-producing cells administered, in order to block side effects without blocking the main anti-tumor effect of TNF.
  • One of ordinary skill in the art will know how to determine such doses without undue experimentation.
  • TNF ⁇ is of major importance in the pathogenesis of rheumatoid arthritis.
  • Evidence for the production of TNF ⁇ is present in rheumatoid arthritis joint tissues and synovial fluid at the protein and mRNA level (Buchan G, et al . , Clin . Exp . Immunol 73 : 449-455, 1988), indicating local synthesis.
  • detecting TNF ⁇ in rheumatoid arthritis joints even in quantities sufficient for bioactivation does not necessarily indicate that it is important in the pathogenesis of rheumatoid arthritis, nor that it is a good candidate therapeutic target.
  • TNF mAb To facilitate clinical study of TNF mAb a high-affinity potent inhibiting and/or neutralizing mouse anti-human TNF IgGl mAb designated A2 was produced.
  • mice Female BALB/c mice, 10 weeks old, were obtained from the Jackson Laboratory (Bar Harbor, ME) . Forty ⁇ g of purified E. co i-derived recombinant human TNF (rhTNF) emulsified with an equal volume of complete Freund's adjuvant (obtained from Difco Laboratories) in 0.4 ml was injected subcutaneously and intraperitoneally (i.p.) into a mouse. One week later, an injection of 5 ⁇ g of rhTNF in incomplete Freund's adjuvant was given i.p. followed by four consecutive i.p. injections of 10 ⁇ g of TNF without adjuvant. Eight weeks after the last injection, the mouse was boosted i.p. with 10 ⁇ g of TNF.
  • rhTNF E. co i-derived recombinant human TNF
  • Spleen cells were fused with cells of the nonsecreting hybridoma, Sp2/0 (ATCC CRL1581) , at a 4:1 ratio of spleen cells to Sp2/0 cells, in the presence of 0.3 ml of 30% polyethylene glycol, PEG 1450. After incubation at 37 ⁇ * >c for 6 hours, the fused cells were distributed in 0.2 ml aliquots into 96-well plates at concentrations of 2 x 10 4 SP2/0 cells per well. Feeder cells, in the form of 5 x 10 4 normal BALB/c spleen cells, were added to each well.
  • the growth medium used consisted of RPM1-1640 medium, 10% heat-inactivated fetal bovine serum (FBS) (HYCLONE) , 0.1 mM minimum essential medium (MEM) nonessential amino acids, 1 mM sodium pyruvate, 2mM L-glutamine, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin (GIBCO Laboratories) and, for selection, hypoxanthine-aminopterin-thymidine (HAT) (Boehringer Mannheim) .
  • a solid-phase radioimmunoassay (RIA) was employed for screening supernatants for the presence of mAbs specific for rhTNF ⁇ . This assay is described in Example II, below. The background binding in this assay was about 500 cpm. A supernatant was considered positive if it yielded binding of 2000 cpm or higher.
  • the hybridoma line A2 was selected. This line was maintained in RPM1-1640 medium with 10% FBS (GIBCO) , 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 2 mM L-glutamine, 100 U/ml penicillin and 100 ⁇ g/ml streptomycin.
  • anti-TNF antibodies which inhibit TNF biological activity can be screened by binding to peptide including at least 5 amino acids of residues 87-108 or both residues 59-80 and 87-108 of TNF or combinations of peptides contained therein, which are used in place of the rTNF protein, as described above.
  • E. coli-derived rhTNF was diluted to 1 ⁇ g/ml in BCB buffer, pH 9.6, and 0.1 ml of the solution was added to each assay well. After incubation at 4oc overnight, the wells were washed briefly with BCB, then sealed with 1% bovine incubated with 40 pg/ml of natural (GENZYME, Boston, MA) or recombinant (SUNTORY, Osaka, Japan) human TNF ⁇ with varying concentrations of mAb A2 in the presence of 20 ⁇ g/ml cycloheximide at 39°C overnight. Controls included medium alone or medium + TNF in each well.
  • A673/6 cells were seeded at 3 x 10 4 cells/well 20 hr before the TNF bioassay.
  • Two-fold serial dilutions of rhTNF, E. coli-derived recombinant human lymphotoxin (TNFS) , and E. co i-derived recombinant murine TNF were prepared.
  • the A2 hybridoma supernatant was added to an equal volume of the diluted TNF preparations, and the mixtures were incubated at room temperature for 30 min.
  • TNF-1 The inhibiting and/or neutralizing activity of mAb A2 was compared with three other murine mAbs specific for human TNF, termed TNF-1, TNF-2 and TNF-3, and a control mAb.
  • TNF-1, TNF-2 and TNF-3 Three other murine mAbs specific for human TNF, termed TNF-1, TNF-2 and TNF-3, and a control mAb.
  • rhTNF 40 pg/ml
  • J region DNA probes can be used to screen genomic libraries to isolate DNA linked to the J regions. Although DNA in the germline configuration (i.e., unrearranged) would also hybridize to J probes, this DNA would not be linked to a Ig V region sequence and can be identified by restriction enzyme analysis of the isolated clones.
  • the cloning utilized herein was to isolate V regions from rearranged H and L chain genes using J H and J k probes. These clones were tested to see if their sequences were expressed in the A2 hybridoma by Northern analysis. Those clones that contained expressed sequence were cloned into expression vectors containing human C regions and transfected into mouse myeloma cells to determine if an antibody was produced. The antibody from producing cells was then tested for binding specificity and functionally compared to the A2 murine antibody.
  • a size-selected genomic library was constructed using the phage lambda vector charon 27.
  • High molecular weight DNA was isolated from A2 hybridoma cells and digested to completion with restriction endonuclease Hindlll. The DNA was then fractionated on a 0.8% agarose gel and the DNA fragments of three different size ranges of approximately 3 kb, 4 kb and 6 kb were isolated from the gel by electroelution.
  • the size ranges for library construction were chosen based upon the size of Hind III fragments that hybridized on a southern blot with the J k probe.
  • DNA fragments from each size class were ligated with lambda charon 27 arms and packaged into phage particles in vi tro using Gigapack Gold from Stratagene (LaJolla, CA) .
  • the mouse L chain J k probe was a 2.7 kb Hindlll fragment containing all five J k segments.
  • the probe was labeled with 32 P by random priming using a kit obtained from Boehringer Mannheim. Free nucleotides were removed by centrifugation through a Sephadex G-SO column. The specific activities of the probe was approximately 10 9 cpm/ ⁇ g.
  • Plaque hybridizations were carried out in 5x SSC, 50% formamide, 2x Denhardt's reagent, and 200 ⁇ g/ml denatured salmon sperm DNA at 42°C for 18-20 hours. Final washes were in 0.5x SSC, 0.1% SDS at 65oC. Positive clones were identified after autoradiography.
  • EXAMPLE V Construction of H Chain Genomic Library
  • a genomic library was constructed in the lambda g lO vector system. High molecular weight DNA was digested to completion with restriction endonuclease EcoRI and fragments of approximately 7.5 kb were isolated after agarose gel electrophoresis. These fragments were ligated with lambda gtlO arms and packaged into phage particles in vi tro using Gigapack Gold.
  • This library was screened at a density of 20,000 plaques per 150 mm plate using a J H probe.
  • the J H probe was a 2kb BamHI/EcoRI fragment containing both J3 and J4 segments.
  • the probe was labeled as in Example III and had a similar specific radioactivity. Hybridization and wash conditions were identical to those used in Example III.
  • EXAMPLE VI Cloning of the TNF-Specific V gene regions Several positive clones were isolated from the H and L chain libraries after screening approximately 10 6 , plaques from each library using the J H and J k probes, respectively. Following plaque purification, bacteriophage DNA was isolated for each positive clone, digested with either EcoRI (H chain clones) or Hindlll (L chain clones) and fractionated on 1% agarose gels. The DNA was transferred to nitrocellulose and the blots were hybridized with the J H or the J k probe.
  • EcoRI H chain clones
  • Hindlll L chain clones
  • H chain clones were obtained that contained 7.5 k/D EcoRI DNA encoding fragments of MAbs to the J H probe.
  • For the light chain libraries several clones from each of the three size-selected libraries were isolated that contained Hindlll fragments that hybridize to the J k probe.
  • For the L chain several independently derived Hindlll fragments of 2.9 kb from the 2 kb library hybridized with a 1250 bp mRNA from A2, but not with SP2/0 mRNA (see Example VII) .
  • Hindlll fragments derived from the 4 kb library hybridized both to the A2 mRNA and the fusion partner mRNA.
  • a 5.7 kb Hindlll fragment from the 6 kb library did not hybridize to either RNA.
  • the observed lengths of hybridizing A2 mRNA were the correct sizes for H and L chain mRNA, respectively. Because the RNA expression was restricted to the A2 hybridoma, it was assumed that the 7.5 kb H chain fragments and the 2.9 kb L chain fragments contained the correct V region sequences from A2.
  • One example of each type was chosen for further study. The important functional test is the demonstration that these V region sequences, when combined with appropriate C region sequences, are capable of directing the synthesis of an antibody with a specificity and affinity similar to that of the murine A2 antibody.
  • the 7.5 kb H chain fragment and the 2.9 kb L chain fragment were subcloned into plasmid vectors that allow expression of the chimeric mouse/human proteins in murine myeloma cells (see Examples VIII and IX) . These plasmids were co-transfected into SP2/0 cells to ascertain if intact antibody molecules were secreted, and if so, if they were of the correct specificity and affinity. Control transfections were also performed pairing the putative anti-TNF H chain with an irrelevant, but expressed, L chain; the putative anti-TNF L chain was also paired with an irrelevant, but expressed, H chain. The results indicated that the 7.5 kb H chain fragment could be expressed, whereas the 2.9 kb L chain fragment could not. This was confirmed by DNA sequence analysis that suggested portions of the coding region were not in the proper amino acid reading frame when compared to other known L chain amino acid sequences.
  • the 4.0 kb and 5.7 kb Hindlll fragments isolated from L chain libraries were cloned into expression vectors and tested for expression of chimeric antibody after co-transfection with the 7.5 kb H chain.
  • the 5.7 kb Hindlll fragment was incapable of supporting antibody expression, whereas the 4.0 kb Hindlll fragment did support antibody expression.
  • the antibody resulting from the co-transfection of the 7.5 kb putative H chain V region and the 4.0 kb L chain V region was purified, tested in solid phase TNF binding assay, and found to be inactive.
  • the original (non-functional) 2.9 kb fragment (designated clone 8.3) was missing an AccI site present in some other clones (represented by clone 4.3) .
  • the DNA sequence of clone 4.3 was extremely similar to clone 8.3, but contained a single amino acid reading frame with close homology to known L chains, unlike clone 8.3.
  • the 2.9 kb Hindlll fragment from clone 4.3 was subcloned into the L chain expression vector and co-transfected with the putative anti-TNF H chain into SP2/0 cells. An antibody was synthesized, purified and tested in the solid phase TNF binding assay.
  • the A2 murine hybridoma has been shown to contain at least four rearranged L chain V region genes . At least two of these are expressed as proteins: clone 4.3 (the correct anti-TNF L chain gene) and the gene contained in the 4.0 kb Hindlll fragment (contributed by the fusion partner) .
  • the expression of two L chains implies that the resulting antibody secreted from the murine hybridoma is actually a mixture of antibodies, some using the correct L chain, some using the incorrect L chain, and some using one of each.
  • the presence of two different L chains in the murine A2 antibody has been confirmed by SDS gel and N-terminal protein sequence analysis of the purified antibody. Because construction of the chimeric A2 antibody involves cloning the individual H and L chain genes and expressing them in a non-producing cell line, the resulting antibody will have only the correct L chain and therefore should be a more potent antibody (see Examples X, XI and XII) .
  • the 7.5 kb EcoRI H chain fragment hybridized with a 2 kb mRNA from A2, but not with SP2/0 mRNA.
  • the 2.9 kb L chain Hindlll fragment (clone 4.3) hybridized with a 1250 bp mRNA from A2, but not with SP2/0 mRNA.
  • the observed lengths of A2 mRNA hybridizing were the correct sizes for H and L chain mRNA, respectively, confirming that the V region sequences on these DNA fragments are expressed in A2 hybridoma cells.
  • the putative L (clone 4.3) and H chain V genes described above were joined to human kappa and gammal constant region genes in expression vectors.
  • Example IX - Expression of Chimeric Antibody Genes To express the chimeric H and L chain genes, the expression plasmids were transfected into cells of the non-producing mouse myeloma cell line, SP2/0. Plasmid DNA to be transfected was purified by centrifuging to equilibrium in ethidium bromide/cesium chloride gradients twice. Plasmid DNA (10-50 ⁇ g) was added to 10 7 SP2/0 cells in medium containing Hank's salts, and the mixture was placed in a BIORAD electroporation apparatus. Electropora- tion was performed at 20 volts, following which the cells were plated in 96 well microtiter plates.
  • Mycophenolic acid selection was applied after 24 hours and drug resistant colonies were identified after 1-2 weeks. Resistant colonies were expanded to stable cell lines and tissue culture supernatant from these cell lines was tested for antibody using an ELISA assay with goat anti-human IgG Fc antibody and goat anti-human H+L conjugated with alkaline phosphatase (obtained from Jackson Laboratories) .
  • the chimeric A2 antibody was purified from tissue culture supernatant by Protein A-Sepharose chromatography. The supernatant was adjusted to 0. IM Tris, 0.002M EDTA, pH 8.0 and loaded on a Protein A-Sepharose column equilibrated in the same buffer. The IgG was eluted with 0. IM citrate, pH 3.5, inhibited or neutralized with IM Tris, and dialyzed into phosphate buffered saline (PBS) .
  • PBS phosphate buffered saline
  • the purified chimeric antibody was evaluated for its binding and inhibiting and/or neutralizing activity.
  • Such high affinity anti-TNF antibodies having affinities of binding to TNF ⁇ of at least 1 x 10 8 "•*** , more preferably at least 1 x 10 9 M “1 (expressed as Ka) are preferred for immunoassays which detect very low levels of TNF in biological fluids.
  • anti-TNF antibodies having such high affinities are preferred for therapy of TNF- ⁇ -mediated conditions or pathology states.
  • the specificity of cA2 for TNF was confirmed by testing for cross-neutralization of human lymphotoxin (TNF-/3) . Lymphotoxin shares some sequence homology and certain biological activities, for example, tumor cell cytotoxicity, with TNF (Pennica, et al .
  • A2 or cA2 The ability of A2 or cA2 to react with TNF from different animal species was also evaluated.
  • TNF TNF has bioactivity in a wide range of host animal species.
  • certain inhibiting and/or neutralizing epitopes on human TNF are conserved amongst different animal species and others appear to be restricted to humans and chimpanzees.
  • Neutralization experiments utilized endotoxin-activated cell supernatants from freshly isolated human, chimpanzee, rhesus and cynomolgus monkey, baboon, pig, dog, rabbit, or rat monocytes as the TNF source.
  • murine mAb A2 inhibited or neutralized activity of only human and chimpanzee TNF, and had no effect on TNF derived from other primates and lower animals. A2 also did not inhibit or neutralize the cytotoxic effect of recombinant mouse TNF.
  • the epitope recognized by A2 is one shared by human and chimpanzee TNF ⁇ .
  • Chimeric A2 was also tested in this manner for cross-reactivity with monocyte-derived TNF from rat, rabbit, dog and pig, as well as with purified recombinant mouse TNF ⁇ , and natural and recombinant human
  • Both the murine and chimeric anti-TNF ⁇ antibodies, A2 and cA2 were determined to have potent TNF-inhibiting and/or neutralizing activity.
  • murine A2 at a concentration of about 125 ng/ml completely inhibited or neutralized the biological activity of a 40 pg/ml challenge of rhTNF ⁇ .
  • Two separate determinations of inhibiting and/or neutralizing potency, expressed as the 50% Inhibitory Dose (ID50) were determined to be 15.9 ⁇ 1.01 and 17.9 ⁇ 1.6 ng/ml (Mean + Std error) .
  • ID50 50% Inhibitory Dose
  • TNF-I murine anti-TNF ⁇ antibodies
  • TNF-2 murine anti-TNF ⁇ antibodies
  • cA2 also inhibited or neutralized both natural and rhTNF in a dose-dependent manner in the cytotoxicity assay.
  • levels of cA2 as low as 125 ng/ml completely abolished the toxic activity of TNF.
  • the cA2 exhibited greater TNF-inhibiting and/or neutralizing activity than did the parent murine A2 mAb.
  • Such inhibiting and/or neutralizing potency at antibody levels below 1 ⁇ g/ml, can easily be attained in the blood of a subject to whom the antibody is administered. Accordingly, such highly potent inhibiting and/or neutralizing anti-TNF antibodies, in particular the chimeric antibody, are preferred for therapeutic use in TNF ⁇ -mediated pathologies or conditions.
  • TNF induces cellular secretion of IL-6.
  • IL-6 is involved in the pathophysiology of sepsis, although the precise role of IL-6 in that syndrome is unclear (Fong, et al . , J. Exp . Med. 170:1627-1633 (1989) ; Starnes Jr., et al . , J. Immunol , 145:4185-4191 (1990)) .
  • the ability of cA2 to inhibit or neutralize TNF-induced IL-6 secretion was evaluated using cultured human diploid FS-4 fibroblasts. The results in Table 1 show that cA2 was effective in blocking IL-6 secretion in cells that had been incubated overnight with TNF. TNF-induced IL-6 secretion was not inhibited in the absence of a mAb or in the presence of a control mAb specific for an irrelevant antigen.
  • Control mAb ⁇ 0.20 1.60 1.96 2.16 cA2 ⁇ 0.20 ⁇ 0.20 ⁇ 0.20 0.30
  • TNF TNF-induced activation of cultured human umbilical vein endothelial cells
  • TNF stimulation of procoagulant activity was determined by exposing intact cultured HUVEC cells to TNF (with or without antibody) for 4 hours and analyzing a cell lysate in a human plasma clotting assay.
  • the results in Table 2 show the expected upregulation by TNF of HUVEC procoagulant activity (reflected by a decreased clotting time) .
  • Chimeric antibody cA2 effectively inhibited or neutralized this TNF activity in a dose-dependent manner.
  • Control Ab is a chimeric mouse/human IgGl anti-CD4 antibody.
  • TNF In addition to stimulating procoagulant activity, TNF also induces surface expression of endothelial cell adhesion molecules such as ELAM-1 and ICAM-1.
  • endothelial cell adhesion molecules such as ELAM-1 and ICAM-1.
  • the ability of cA2 to inhibit or neutralize this activity of TNF was measured using an ELAM-1 specific detection radioimmunoassay.
  • Cultured HUVEC were stimulated with 250 ng/ml rhTNF (Dainippon, Osaka, Japan) with or without antibody at 37oC overnight in a 96-well plate format.
  • Surface expression of ELAM-1 was determined by sequential addition of a mouse anti-human ELAM-1 mAb and 125 I-labelled rabbit anti-mouse immunoglobulin second antibody directly to culture plates at 4°C.
  • TNF induced the expression of ELAM-1 on the surface of cultured HUVEC cells, and this activity was again effectively blocked in a dose-related manner by cA2.
  • TNF is known to stimulate mitogenic activity in cultured fibroblasts.
  • Chimeric A2 inhibited or neutralized TNF-induced mitogenesis of human diploid FS-4 fibroblasts cultures, confirming the potent inhibiting and/or neutralizing capability of cA2 against a broad spectrum of in vi tro TNF biological activities.
  • FMOC-L-Ala-OPfp FMOC-L-Cys (Trt) -OPfp
  • FMOC-L-Asp(OtBu) -OPfp FMOC-L-Giu (OtBu) -OPfp
  • FMOC-L-Phe-OPfp FMOC-Gly-OPfp, FMOC-L-His (Boc) -OPfp, FMOC-L-Ile-OPfp, FMOC-L-Lys (Boc) -OPfp, FMOC-L- Leu-OPfp, FMOC-L-Asn-OPfp, FMOC-L-Pro-OPfp, FMOC-L-Gin- OPfp, FMOC-L-Arg(Mtr) -OPfp, FMOC-L-Ser(tBu) -ODhbt, FMOC-L-Thr (tBu) -ODhbt, FMOC-L-Val-OPfp, FMOC-L-Trp-OPfp,
  • FMOC-L-Try(tBu) -OPfp, and 1-hydrox-fbenotriazol (HOBT) were obtained from Cambridge Research Biochemicals .
  • l-Methyl-2-Pyrrolidinone (NMP) was obtained from EM Science; Methanol from JT Baker; Acetic Anhydride from Applied
  • Trifluoroaccetic acid from Applied Biosystems, Inc.
  • DIEA Diisopropylamne
  • DTT Dithiothreitol
  • HCl Hydrochloric Acid
  • FMOC 9-fluorenylmethoxycarbonyl
  • tBu t-butyl ether OrB, t-butyl ester
  • Boc t-butyloxycarbonyl
  • Mtr 4-methoxy-2, 3, 6-trimethyl- benzenesulfonyl
  • Trt trityl
  • OPfp pentafluorophenylester
  • ODhbt oxo-benzotriazone ster.
  • a chimeric antibody of the present invention designated cA2
  • cA2 was used to determine which portions of the TNF amino acid sequence were involved in inhibitory binding by the antibody by epitope mapping, whereby the amino acid sequences of TNF- ⁇ recognized by cA2 have been identified.
  • the complete primary sequence of human TNF ⁇ is disclosed in Nature 312:724-729 (1984) .
  • Overlapping decapeptides beginning with every second amino acid and covering the entire amino acid sequence of human T ⁇ F- ⁇ were synthesized on polyethylene pins using the method of Gysen (Gysen et al . , Peptides : Chemistry and Biological , Proceedings of the Twelfth American Peptide Symposium, p. 519-523, Ed, G.R.
  • cA2 There are at least two non-contiguous peptide sequences of T ⁇ F- ⁇ recognized by cA2.
  • the cA2 mAb recognizes an epitope composed at least in part of amino acids located within residues 87-108 or both residues 59-80 and 87-108 of T ⁇ F.
  • the mAb cA2 blocks the action of T ⁇ F- ⁇ without binding to the putative receptor binding locus, which can include one or more of, e.g., 11-13, 37-42, 49-57 or 155-157 of hTNF ⁇ .
  • Preferred anti-TNF mAbs are those that inhibit this binding of human TNF- ⁇ to its receptors by virtue of their ability to bind to one or more of these peptide sequences. These antibodies can block the activity of TNF by virtue of binding to the cA2 epitope, such binding demonstrated to inhibit TNF activity.
  • the identification of those peptide sequences recognized by cA2 provides the information necessary to generate additional mAbs with binding characteristics and therapeutic utility that parallel the embodiments of this application.
  • a synthesis schedule was generated using the CRB epitope mapping software. Prior to the first amino acid coupling, the pins were deprotected with a 20% piperidine in NMP solution for 30 minutes at room temperature. After deprotected, the pins were washed with NMP for five minutes at room temperature, followed by three methanol washes. Following the wash steps, the pins were allowed to air dry for at least 10 minutes. The following procedure was performed for each coupling cycle:
  • the HOBT was dissolved in the appropriate amount of NMP according to the synthesis schedule.
  • the amino acid derivatives were dissolved in the recommended amount of HOBT solution and 150 microliters were pipeted into the appropriate wells as directed by the well position sheet of the synthesis schedule.
  • the peptide pins were washed, deprotected and treated with 150 microliters of a solution containing NMP; acetic anhydride : triethylamine (5:2:1) for 90 minutes at 30°C, followed by the washing procedure outlined above.
  • the second set of peptide pins was deprotected by not acetylated to give free N-terminal amino groups.
  • a 10 x concentrate was prepared by dissolving sodium dihydrogen phosphate (3.90 g, Sigma cat # S-0751 or equivalent), disodium hydrogen phosphate (10.70 g, Baker cat #3828-1 or equivalent) and sodium chloride (85.0 g, Baker cat #3624-5 or equivalent) in 1.0 L of milliQ water. The pH was adjusted to 7.2 ⁇ 0.1 with 50% w/w sodium hydroxide (VWR cat #VW 6730 or equivalent) . To the solution was added Tween 20 (5.0 mL, Sigma cat #P-1379 or equivalent) , and the mixture stirred gently. Just prior to use 100 mL of this solution was diluted to 1.0 L with milliQ water. Substrate solution
  • Substrate buffer was prepared by dissolving citric acid (4.20g, Malinckrodt cat #0627 or equivalent) and disodium hydrogen phosphate (7.10 g, Baker cat #3828-1 or equivalent) in 1.0 L of milliQ water. The pH was adjusted to 5.00 with 50% w/w sodium hydroxide (VWR cat #VW6730-3 or equivalent) . Immediately prior to use an OPD substrate tablet (30 mg, Sigma cat #P-8412 or equivalent and 30% (v/v) hydrogen peroxide (40 ⁇ L, Sigma cat #P-1379 or equivalent) were added to the substrate buffer 25.0 mL) .
  • the solution was wrapped in foil and mixed thoroughly.
  • Disruption buffer 2.0 L was heated to 60° and placed in an ultra-sonic bath in a fume hood.
  • dithiolthreitol 2.5 g, Sigma cat #D-0632 or equivalent
  • the peptide pins were sonicated in this medium for 30 min, washed thoroughly with milliQ waster, suspended in a boiling ethanol bath for 2 min, and air-dried.
  • Blocking buffer 200 ⁇ L was added to a 96 well disposable polystyrene Elisa plate and the peptide pins suspended in the wells.
  • the peptide pins and plate were incubated for 2 hours at room temperature on an oscillating table shaker. The plates and peptide pins were washed with PBS/Tween 20 (four times) . To each well was added a 20 ⁇ g/ml concentration of cA2 antibody (diluted with blocking buffer, 175 ⁇ L/well) . TNF competition was done by incubation of TNF ⁇ (40 ⁇ g/ml) and cA2 (20 ⁇ g/ml) in BSA/ovalbumin/ BBS for three hours at room temperature. The peptide pins were suspended in the plate and incubated at 4° overnight. The peptide pins and plate were washed with PBS/Tween 20 (four times) .
  • mice Female BALB/c mice, as in Example I above, are injected subcutaneously and intraperitoneally (i.p.) with forty ⁇ g of purified E. coli-derived recombinant human TNF (rhTNF) fragments comprising anti-TNF epitopes of at least 5 amino acids located within the non-contiguous sequence 59-80,
  • rhTNF E. coli-derived recombinant human TNF
  • Spleen cells are fused with cells of the nonsecreting hybridoma, Sp2/0 (ATCC CRL1581) , at a 4:1 ratio of spleen cells to Sp2/0 cells, in the presence of 0.3 ml of 30% polyethylene glycol, PEG 1450. After incubation at 37 ⁇ c for 6 hours, the fused cells are distributed in 0.2 ml aliquots into 96-well plates at concentrations of 2 x 10 4 SP2/0 cells per well. Feeder cells, in the form of 5 x 10 4 normal BALB/c spleen cells, are added to each well.
  • the growth medium used consisted of RPMI-1640 medium, 10% heat-inactivated fetal bovine serum (FBS) (Hyclone) , 0.1 mM MEM nonessential amino acids, 1 mM sodium pyruvate,
  • RIA radioimmunoassay
  • a supernatant is considered positive if it yielded binding of 2000 cp or higher.
  • one or more positive supernatants are routinely identified by RIA.
  • the highest binding are subcloned at limiting dilution on mouse feeder cells.
  • one or more antibodies are found to have potent inhibiting and/or neutralizing activity.
  • Murine and chimeric antibodies, fragments and regions are obtained by construction of chimeric expression vectors encoding the mouse variable region of antibodies obtained in Example XIV and human constant regions, as presented in Examples IV-IX above.
  • the resulting chimeric A2 antibody is purified from tissue culture supernatant by Protein A-Sepharose chromatography. The supernatant is adjusted to 0. IM Tris, 0.002M EDTA, pH 8.0 and loaded on a Protein A-Sepharose column equilibrated in the same buffer. The IgG is then eluted with 0.IM citrate, pH 3.5, neutralized with IM Tris, and dialyzed into phosphate buffered saline (PBS) .
  • PBS phosphate buffered saline
  • the purified murine and chimeric antibodies, fragments and regions are evaluated for its binding and inhibiting and/or neutralizing activity.
  • the retreatment program included patients 1, 2, 3, 5, 7, 8, 9 and 10 suffering from rheumatoid arthritis from an open-label trial with cA2. Patients received up to four cycles of treatment, the complete infusion protocol in the open trial being cycle 1. The timing of cycles 2-4 was dictated by disease relapse, defined as the loss of response to the previous cycle. Most cycles were administered within 5 weeks of relapse, but cycle 2 was delayed in 4 patients for administrative reasons. Although 8 patients entered the retreatment program, patient 5 was excluded from the analysis of response because of withdrawal for an adverse event during cycle 2 (see below) . Three patients were withdrawn after cycle 2.
  • the response data therefore derive from 7 patients for cycles 1 and 2, 5 for cycle 3, and 4 for cycle 4.
  • cA2 was administered by intravenous infusion over 2-3 hours. The dose was 30 mg/kg in cycle 1 (in two or four infusions) and 10 mg/kg in a single infusion for cycles 2-4. Patients were admitted overnight for cycle 1, but subsequently were treated as day cases.
  • HACAs Human anti-chimeric A2 antibody responses
  • False-positive signals due to rheumatoid factor anti-Fc antibodies were eliminated by the addition of covalently polymerized human Fc to the HACA sample diluent. Samples containing over 200 ng/mL cA2 (independent assay for free cA2) were considered likely to give a false-negative result for HACA, and were disqualified from analysis.
  • Patient 9 developed a high- titre HACA (640) after cycle 2, but her cycle 3 response duration of 8.7 weeks was no different from her cycle 1 duration (8 weeks) . Conversely, no HACA was detected in patient 8, but her response duration fell from 17.4 weeks in cycle 1 to 8.3 in cycle 3.
  • HACAs specific for the murine portion of cA2 were eventually detected in half of the patients in the retreatment program. These were mostly low titre and 2 patients were successfully retreated despite their presence. Similar antiglobulin responses were seen in 3 of 4 rheumatoid arthritis patients treated with repeated injections of a humanized monoclonal antibody to CD252, suggesting that antibody reshaping does not entirely eliminate immunogenicity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un procédé pour traiter un individu souffrant d'une maladie liée au facteur nécrosant des tumeurs, consistant à administrer à cet individu des doses multiples d'anticorps anti-TNF, où la seconde dose ou les doses subséquentes sont administrées pendant ou immédiatement avant une rechute due à la maladie. De préférence, la maladie est une maladie liée au facteur TNFα, comme par exemple la polyarthrite rhumatoïde. Cet anticorps anti-TNF peut être un anticorps monoclonal ou l'un de ses fragments, par exemple il peut s'agir d'un anticorps murin, d'un anticorps chimère, d'un anticorps humanisé ou de fragments de ceux-ci. De préférence, l'anticorps se fixe à un ou à plusieurs acides aminés du facteur TNFα humain (hTNFα) choisis dans le groupe 87-108 et 59-80. L'anticorps peut se fixer à l'épitope de A2 ou cA2. Dans la forme d'exécution préférée, l'anticorps est A2 ou cA2.
PCT/US1995/005155 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf) WO1996033204A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP8531685A JPH11503752A (ja) 1995-04-20 1995-04-20 抗ｔｎｆ抗体の複数回投与
PCT/US1995/005155 WO1996033204A1 (fr) 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)
AU23657/95A AU2365795A (en) 1995-04-20 1995-04-20 Multiple administrations of anti-tnf antibody
EP95917696A EP0871641A4 (fr) 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)
CA002218522A CA2218522A1 (fr) 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1995/005155 WO1996033204A1 (fr) 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)
CA002218522A CA2218522A1 (fr) 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US44667495A A-371-Of-International 1995-05-30 1995-05-30
US10/252,489 Continuation US20030064070A1 (en) 1995-05-30 2002-09-23 Multiple administrations of anti-TNF antibody

Publications (1)

Publication Number Publication Date
WO1996033204A1 true WO1996033204A1 (fr) 1996-10-24

Family

ID=25679734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/005155 WO1996033204A1 (fr) 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)

Country Status (4)

Country Link
EP (1) EP0871641A4 (fr)
AU (1) AU2365795A (fr)
CA (1) CA2218522A1 (fr)
WO (1) WO1996033204A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005357A1 (fr) * 1996-08-01 1998-02-12 The Kennedy Institute Of Rheumatology Anticorps anti facteur de necrose tumorale et methotrexate dans le traitement des maladies auto-immunes
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US7494652B1 (en) 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
US7977464B2 (en) 2000-06-06 2011-07-12 Ucb Pharma S.A. Antibody molecules specific to human tumour necrosis factor alpha
US8889136B2 (en) 2004-04-09 2014-11-18 Abbvie Biotechnology Ltd. Multiple-variable dose regimen for treating TNFα-related disorders
US8986693B1 (en) 2004-04-09 2015-03-24 Abbvie Biotechnology Ltd. Use of TNFα inhibitor for treatment of psoriasis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US11091542B2 (en) 2015-12-18 2021-08-17 UCB Biopharma SRL Antibody molecules which bind TNF alpha

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002078A1 (fr) * 1989-08-07 1991-02-21 Peptide Technology Ltd Ligands de liaison du facteur de necrose de tumeurs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002078A1 (fr) * 1989-08-07 1991-02-21 Peptide Technology Ltd Ligands de liaison du facteur de necrose de tumeurs

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ADERKA ET AL: "THE POSSIBLE ROLE OF TUMOR NECROSIS FACTOR (TNF) AND ITS NATURAL INHIBITORS, THE SOLUBLE-TNF RECEPTORS, IN AUTOIMMUNE DISEASES", ISRAEL JOURNAL OF MEDICAL SCIENCES., ISRAEL MEDICAL ASSOCIATION, TEL AVIV., IL, vol. 28., no. 02., 1 February 1992 (1992-02-01), IL, pages 126 - 130., XP002079556, ISSN: 0021-2180 *
BEUTLER B, ET AL.: "PURIFICATION OF CACHECTIN, A LIPOPROTEIN LIPASE-SUPPRESSING HORMONESECRETED BY ENDOTOXIN BY ENDOTOXIN-INDUCED RAW 264.7 CELLS", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 161, 1 May 1985 (1985-05-01), US, pages 984 - 995, XP002947864, ISSN: 0022-1007, DOI: 10.1084/jem.161.5.984 *
FONG Y, ET AL.: "ANTIBODIES TO CACHECTIN/TUMOR NECROSIS FACTOR REDUCE INTERLEUKIN 1BETA AND INTERLEUKIN 6 APPEARANCE DURING LETHAL BACTEREMIA", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 170, no. 05, 1 November 1989 (1989-11-01), US, pages 1627 - 1633, XP002947866, ISSN: 0022-1007, DOI: 10.1084/jem.170.5.1627 *
GIOVINE DI F S, NUKI G, DUFF G W: "TUMOUR NECROSIS FACTOR IN SYNOVIAL EXUDATES", ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 47, 19 February 1988 (1988-02-19), GB, pages 768 - 772, XP001041392, ISSN: 0003-4967 *
MOELLER A, ET AL.: "MONOCLONAL ANTIBODIES TO HUMAN TUMOR NECROSIS FACTOR ALPHA: IN VITRO AND IN VIVO APPLICATION", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 02, no. 03, 1 May 1990 (1990-05-01), US, pages 162 - 169, XP002947865, ISSN: 1043-4666, DOI: 10.1016/1043-4666(90)90011-H *
See also references of EP0871641A4 *
TRACEY K J, ET AL.: "ANTI-CACHECTIN/TNF MONOCLONAL ANTIBODIES PREVENT SEPTIC SHOCK DURING LETHAL BACTERAEMIA", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 330, 17 December 1987 (1987-12-17), United Kingdom, pages 662 - 664, XP002947867, ISSN: 0028-0836, DOI: 10.1038/330662a0 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846442B2 (en) 1992-10-08 2010-12-07 The Mathilda And Terence Kennedy Institute Of Rheumatology Trust Methods of treating rheumatoid arthritis with an anti-TNF-alpha antibodies and methotrexate
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
EP1941904B1 (fr) * 1996-08-01 2012-05-16 The Mathilda And Terrence Kennedy Institute Of Rheumatology Trust Antagonistes du TNF pour utilisation dans une thérapie adjuvante au méthotrexate dans le traitement des maladies autoimmunes
US7838489B2 (en) 1996-08-01 2010-11-23 The Mathilda And Terence Kennedy Institute Of Rheumatology Trust Methods of treating rheumatoid arthritis with p75 TNF-alpha receptor and methotrexate
EP1593393A2 (fr) 1996-08-01 2005-11-09 The Kennedy Institute Of Rheumatology Anticorps contre le TNF et methotrexate pour le traitement de maladies autoimmunes
US8383120B2 (en) 1996-08-01 2013-02-26 The Mathilda And Terence Kennedy Institute Of Rheumatology Trust Concomitant treatment of rheumatoid arthritis with anti-TNF-alpha antibodies and methotrexate
EP1941904A2 (fr) 1996-08-01 2008-07-09 The Kennedy Institute Of Rheumatology Anticorps anti TNF et méthotrexate dans le traitement des maladies auto-immunes
WO1998005357A1 (fr) * 1996-08-01 1998-02-12 The Kennedy Institute Of Rheumatology Anticorps anti facteur de necrose tumorale et methotrexate dans le traitement des maladies auto-immunes
US8298537B2 (en) 1996-08-01 2012-10-30 The Mathilda And Terence Kennedy Institute Of Rheumatology Trust Concomitant treatment of rheumatoid arthritis with anti-TNF-α antibodies and methotrexate
EP1593393B1 (fr) * 1996-08-01 2011-11-30 The Kennedy Institute Of Rheumatology Anticorps contre le TNF et methotrexate pour le traitement concomitant de maladies autoimmunes
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US6663864B1 (en) 1998-06-10 2003-12-16 Promega Corp. Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
US7494652B1 (en) 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
US7261891B2 (en) 1998-06-10 2007-08-28 Promega Corporation Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
US7977464B2 (en) 2000-06-06 2011-07-12 Ucb Pharma S.A. Antibody molecules specific to human tumour necrosis factor alpha
US9090689B1 (en) 2002-07-19 2015-07-28 Abbvie Biotechnology Ltd. Use of TNFα inhibitor for treatment of psoriasis
US8986693B1 (en) 2004-04-09 2015-03-24 Abbvie Biotechnology Ltd. Use of TNFα inhibitor for treatment of psoriasis
US8961973B2 (en) 2004-04-09 2015-02-24 Abbvie Biotechnology Ltd. Multiple-variable dose regimen for treating TNFα-related disorders
US8889136B2 (en) 2004-04-09 2014-11-18 Abbvie Biotechnology Ltd. Multiple-variable dose regimen for treating TNFα-related disorders
US8961974B2 (en) 2004-04-09 2015-02-24 Abbvie Biotechnology Ltd. Multiple-variable dose regimen for treating TNFα-related disorders
US9061005B2 (en) 2004-04-09 2015-06-23 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
US9187559B2 (en) 2004-04-09 2015-11-17 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
US9499615B2 (en) 2004-04-09 2016-11-22 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
US9512216B2 (en) 2004-04-09 2016-12-06 Abbvie Biotechnology Ltd. Use of TNFα inhibitor
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US11091542B2 (en) 2015-12-18 2021-08-17 UCB Biopharma SRL Antibody molecules which bind TNF alpha

Also Published As

Publication number Publication date
AU2365795A (en) 1996-11-07
EP0871641A1 (fr) 1998-10-21
CA2218522A1 (fr) 1996-10-24
EP0871641A4 (fr) 2001-09-26

Similar Documents

Publication Publication Date Title
US7227003B2 (en) Anti-TNF antibody fragments
US7160543B2 (en) Methods of inhibiting TNF-α in patients with Crohn's disease
US7204985B2 (en) Methods of treating disseminated intravascular coagulation by multiple administration of anti-TNF antibodies
US5656272A (en) Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5919452A (en) Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5698195A (en) Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US20070298040A1 (en) Methods of treating seronegative arthropathy with anti-TNF antibodies
EP0871641A1 (fr) Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)
US20030064070A1 (en) Multiple administrations of anti-TNF antibody
US20020132307A1 (en) Anti-TNF antibodies and peptides of human tumor necrosis factor
JPH11503752A (ja) 抗ｔｎｆ抗体の複数回投与

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: US

Ref document number: 1995 446674

Date of ref document: 19950530

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2218522

Country of ref document: CA

Ref country code: CA

Ref document number: 2218522

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1996 531685

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995917696

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995917696

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995917696

Country of ref document: EP